Why a cut-and-paste approach to digital transformation won’t cut it: An interview with the founder of Biocon

Apart from this, I continued with my daily dose of vitamin C, vitamin D, zinc, baby aspirin, chyavanprash, and, twice a week, a 200-milligram dose of hydroxychloroquine. Biocon is a global biopharmaceuticals company that manufactures generic active pharmaceutical ingredients (APIs) and develops novel products for metabolics, oncology, immunotherapy, nephrology, and other needs. The Indian pharmaceutical sector has a huge global market share of vaccines and generic drugs—50 percent and 20 percent, respectively—but when you look at the value capture, it’s only 3 percent. [...]I think it’s a good model for Asian companies.